PYC THERAPEUTICS LIMITED — Director's Dealing 2015

Aug 13, 2015

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PHYLOGICA LIMITED ABN 48 098 391 961

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the following the director for the purposes of section	information under listing rule 3.19A.2 and as agent for 205G of the Corporations Act.
Name of Director	RICHARD MILES HOPKINS
Date of last notice	24th DECEMBER 2014

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	(1) MAYA VANDEN DRIESEN Wife (2) VANHOP PTY LTD Director of Trustee & Beneficiary of fund
Date of change	14THAUGUST 2015
No. of securities held prior to change	DIRECT: - 7,710,121 ORDINARY SHARES - 1,980,000 ORDINARY SHARES RESTRICTED 03/06/14 - 1,980,000 ORDINARY SHARES RESTRICTED 03/06/15 - 2,040,000 ORDINARY SHARES RESTRICTED 03/06/16 - 211,864 PYCOA OPTIONS EXERCISABLE AT $0.09 EXPIRING 30/06/16 INDIRECT: (1) MAYA VANDEN DRIESEN - 274,924 ORDINARY SHARES (2) VANHOP PTY LTD - 2,502,566 ORDINARY SHARES - 292,398 PYCOA OPTIONS EXERCISABLE AT $0.09 EXPIRING 30/06/16 - 6,500,000 UNLISTED OPTIONS EXERCISABLE AT $0.025 EXPIRING 23/09/2017

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	ORDINARY SHARES
Number acquired	DIRECT 9,222,510 INDIRECT (1) 274,924 (2)2,502,566
Nature of change Example: on‐market trade, off‐market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy‐back	ALLOTMENT PURSUANT TO ENTITLEMENT ISSUE COMPLETION
Number disposed	NIL
Value/Consideration Note: If consideration is non‐cash, provide details and estimated valuation	$120,000.00
No. of securities held after change	DIRECT: - 16,932,631 ORDINARY SHARES - 1,980,000 ORDINARY SHARES RESTRICTED 03/06/14 - 1,980,000 ORDINARY SHARES RESTRICTED 03/06/15 - 2,040,000 ORDINARY SHARES RESTRICTED 03/06/16 - 211,864 PYCOA OPTIONS EXERCISABLE AT $0.09 EXPIRING 30/06/16 INDIRECT: (3) MAYA VANDEN DRIESEN - 549,848 ORDINARY SHARES (4) VANHOP PTY LTD - 5,005,132 ORDINARY SHARES - 292,398 PYCOA OPTIONS EXERCISABLE AT $0.09 EXPIRING 30/06/16 - 6,500,000 UNLISTED OPTIONS EXERCISABLE AT $0.025 EXPIRING 23/09/2017

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
Ifprior written clearance wasprovided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3